Cargando…

BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies

In this work, BTEAC (benzyl triethylammonium chloride) was employed as a phase transfer catalyst in an improved synthesis (up to 88% yield) of S-alkylated bromobenzofuran-oxadiazole scaffolds BF1-9. These bromobenzofuran-oxadiazole structural hybrids BF1-9 were evaluated in vitro against anti-hepato...

Descripción completa

Detalles Bibliográficos
Autores principales: Irfan, Ali, Zahoor, Ameer Fawad, Rasul, Azhar, Al-Hussain, Sami A., Faisal, Shah, Ahmad, Sajjad, Noor, Rida, Muhammed, Muhammed Tilahun, Zaki, Magdi E. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917671/
https://www.ncbi.nlm.nih.gov/pubmed/36769327
http://dx.doi.org/10.3390/ijms24033008
_version_ 1784886423879417856
author Irfan, Ali
Zahoor, Ameer Fawad
Rasul, Azhar
Al-Hussain, Sami A.
Faisal, Shah
Ahmad, Sajjad
Noor, Rida
Muhammed, Muhammed Tilahun
Zaki, Magdi E. A.
author_facet Irfan, Ali
Zahoor, Ameer Fawad
Rasul, Azhar
Al-Hussain, Sami A.
Faisal, Shah
Ahmad, Sajjad
Noor, Rida
Muhammed, Muhammed Tilahun
Zaki, Magdi E. A.
author_sort Irfan, Ali
collection PubMed
description In this work, BTEAC (benzyl triethylammonium chloride) was employed as a phase transfer catalyst in an improved synthesis (up to 88% yield) of S-alkylated bromobenzofuran-oxadiazole scaffolds BF1-9. These bromobenzofuran-oxadiazole structural hybrids BF1-9 were evaluated in vitro against anti-hepatocellular cancer (HepG2) cell line as well as for their in silico therapeutic potential against six key cancer targets, such as EGFR, PI3K, mTOR, GSK-3β, AKT, and Tubulin polymerization enzymes. Bromobenzofuran structural motifs BF-2, BF-5, and BF-6 displayed the best anti-cancer potential and with the least cell viabilities (12.72 ± 2.23%, 10.41 ± 0.66%, and 13.08 ± 1.08%), respectively, against HepG2 liver cancer cell line, and they also showed excellent molecular docking scores against EGFR, PI3K, mTOR, and Tubulin polymerization enzymes, which are major cancer targets. Bromobenzofuran-oxadiazoles BF-2, BF-5, and BF-6 displayed excellent binding affinities with the active sites of EGFR, PI3K, mTOR, and Tubulin polymerization enzymes in the molecular docking studies as well as in MMGBSA and MM-PBSA studies. The stable bindings of these structural hybrids BF-2, BF-5, and BF-6 with the enzyme targets EGFR and PI3K were further confirmed by molecular dynamic simulations. These investigations revealed that 2,5-dimethoxy-based bromobenzofuran-oxadiazole BF-5 (10.41 ± 0.66% cell viability) exhibited excellent cytotoxic therapeutic efficacy. Moreover, computational studies also suggested that the EGFR, PI3K, mTOR, and Tubulin polymerization enzymes were the probable targets of this BF-5 scaffold. In silico approaches, such as molecular docking, molecular dynamics simulations, and DFT studies, displayed excellent association with the experimental biological data of bromobenzofuran-oxadiazoles BF1-9. Thus, in silico and in vitro results anticipate that the synthesized bromobenzofuran-oxadiazole hybrid BF-5 possesses prominent anti-liver cancer inhibitory effects and can be used as lead for further investigation for anti-HepG2 liver cancer therapy.
format Online
Article
Text
id pubmed-9917671
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99176712023-02-11 BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies Irfan, Ali Zahoor, Ameer Fawad Rasul, Azhar Al-Hussain, Sami A. Faisal, Shah Ahmad, Sajjad Noor, Rida Muhammed, Muhammed Tilahun Zaki, Magdi E. A. Int J Mol Sci Article In this work, BTEAC (benzyl triethylammonium chloride) was employed as a phase transfer catalyst in an improved synthesis (up to 88% yield) of S-alkylated bromobenzofuran-oxadiazole scaffolds BF1-9. These bromobenzofuran-oxadiazole structural hybrids BF1-9 were evaluated in vitro against anti-hepatocellular cancer (HepG2) cell line as well as for their in silico therapeutic potential against six key cancer targets, such as EGFR, PI3K, mTOR, GSK-3β, AKT, and Tubulin polymerization enzymes. Bromobenzofuran structural motifs BF-2, BF-5, and BF-6 displayed the best anti-cancer potential and with the least cell viabilities (12.72 ± 2.23%, 10.41 ± 0.66%, and 13.08 ± 1.08%), respectively, against HepG2 liver cancer cell line, and they also showed excellent molecular docking scores against EGFR, PI3K, mTOR, and Tubulin polymerization enzymes, which are major cancer targets. Bromobenzofuran-oxadiazoles BF-2, BF-5, and BF-6 displayed excellent binding affinities with the active sites of EGFR, PI3K, mTOR, and Tubulin polymerization enzymes in the molecular docking studies as well as in MMGBSA and MM-PBSA studies. The stable bindings of these structural hybrids BF-2, BF-5, and BF-6 with the enzyme targets EGFR and PI3K were further confirmed by molecular dynamic simulations. These investigations revealed that 2,5-dimethoxy-based bromobenzofuran-oxadiazole BF-5 (10.41 ± 0.66% cell viability) exhibited excellent cytotoxic therapeutic efficacy. Moreover, computational studies also suggested that the EGFR, PI3K, mTOR, and Tubulin polymerization enzymes were the probable targets of this BF-5 scaffold. In silico approaches, such as molecular docking, molecular dynamics simulations, and DFT studies, displayed excellent association with the experimental biological data of bromobenzofuran-oxadiazoles BF1-9. Thus, in silico and in vitro results anticipate that the synthesized bromobenzofuran-oxadiazole hybrid BF-5 possesses prominent anti-liver cancer inhibitory effects and can be used as lead for further investigation for anti-HepG2 liver cancer therapy. MDPI 2023-02-03 /pmc/articles/PMC9917671/ /pubmed/36769327 http://dx.doi.org/10.3390/ijms24033008 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Irfan, Ali
Zahoor, Ameer Fawad
Rasul, Azhar
Al-Hussain, Sami A.
Faisal, Shah
Ahmad, Sajjad
Noor, Rida
Muhammed, Muhammed Tilahun
Zaki, Magdi E. A.
BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies
title BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies
title_full BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies
title_fullStr BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies
title_full_unstemmed BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies
title_short BTEAC Catalyzed Ultrasonic-Assisted Synthesis of Bromobenzofuran-Oxadiazoles: Unravelling Anti-HepG-2 Cancer Therapeutic Potential through In Vitro and In Silico Studies
title_sort bteac catalyzed ultrasonic-assisted synthesis of bromobenzofuran-oxadiazoles: unravelling anti-hepg-2 cancer therapeutic potential through in vitro and in silico studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917671/
https://www.ncbi.nlm.nih.gov/pubmed/36769327
http://dx.doi.org/10.3390/ijms24033008
work_keys_str_mv AT irfanali bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies
AT zahoorameerfawad bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies
AT rasulazhar bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies
AT alhussainsamia bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies
AT faisalshah bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies
AT ahmadsajjad bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies
AT noorrida bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies
AT muhammedmuhammedtilahun bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies
AT zakimagdiea bteaccatalyzedultrasonicassistedsynthesisofbromobenzofuranoxadiazolesunravellingantihepg2cancertherapeuticpotentialthroughinvitroandinsilicostudies